NASA has announced when the longest total solar eclipse of the century will occur—and you won’t have to wait long. Here’s what you should know. According to NASA's solar eclipse calendar, the longest ...

We're working continuously to improve our search results. If you aren't finding what you expect, please use our feedback form to share the search query and expected result with us so we can improve.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination ...

Microsoft open-sourced the MS-BASIC language. Bill Gates would never have seen this coming back in the day. MS-BASIC 1.1 was many developers' first language. In 1976, they rebranded Altair BASIC to ...

( af Afrikaans Afrikaans | sq Shqiptare Albanian | am አማርኛ Amharic | ar عربى Arabic | hy հայերեն Armenian | az Azərbaycan dili Azerbaijani | eu Euskara Basque | be Беларуская Belarusian | bn বাংলা ...

A total solar eclipse will sweep over parts of Spain, Iceland and Greenland on Aug. 12, 2026, offering millions a chance to witness one of nature's greatest spectacles. As the moon fully blocks the ...

Where to go, how to see it, and why the 2026 eclipse is worth the journey. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. A total solar eclipse ...

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in ...

First patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the ...

CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...